Asia Pacific Mammalian Polyclonal Igg Antibody Market Size & Outlook
Asia Pacific mammalian polyclonal igg antibody market, 2018-2030 (US$M)
Related Markets
Asia Pacific mammalian polyclonal igg antibody market highlights
- The Asia Pacific mammalian polyclonal igg antibody market generated a revenue of USD 213.1 million in 2023.
- The market is expected to grow at a CAGR of 6.6% from 2024 to 2030.
- In terms of segment, goat was the largest revenue generating type in 2023.
- Mouse is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 213.1 million |
| Market revenue in 2030 | USD 332.4 million |
| Growth rate | 6.6% (CAGR from 2023 to 2030) |
| Largest segment | Goat |
| Fastest growing segment | Mouse |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Goat, Rabbit, Horse, Mouse |
| Key market players worldwide | Abcam PLC, Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, New England Biolabs, Stemcell Holdings Inc Ordinary Shares, Phoenix Group Holdings PLC, G-Biosciences, Roche Holding AG |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 17.9% of the global mammalian polyclonal igg antibody market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 332.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Mammalian Polyclonal IgG Antibody Market Scope
Mammalian Polyclonal IgG Antibody Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific mammalian polyclonal igg antibody market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mammalian polyclonal igg antibody market will help companies and investors design strategic landscapes.
Goat was the largest segment with a revenue share of 19.76% in 2023. Horizon Databook has segmented the Asia Pacific mammalian polyclonal igg antibody market based on goat, rabbit, horse, mouse covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific region consists of developed as well as developing countries such as China, India, and other countries. Most of the countries in this region are economically developing and witnessing an increase in the disposable income.
Many multinational companies are heavily investing in this region. In addition, presence of countries such as Japan, which are technologically advanced in terms of healthcare and medical research, is expected to aid in market growth of this region.
Rising number of pharmaceutical and biopharmaceutical companies in countries such as Japan, China, and India are factors anticipated to propel market growth in the region. According to WHO, noncommunicable diseases contributed to 5.8 million deaths in India in 2017 and the number is expected to increase over the next decade.
Reasons to subscribe to Asia Pacific mammalian polyclonal igg antibody market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific mammalian polyclonal igg antibody market databook
-
Our clientele includes a mix of mammalian polyclonal igg antibody market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific mammalian polyclonal igg antibody market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific mammalian polyclonal igg antibody market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific mammalian polyclonal igg antibody market size, by country, 2018-2030 (US$M)
Asia Pacific Mammalian Polyclonal IgG Antibody Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
